Sugi Predict

Sugi Predict / Compounds / SCHEMBL1810729

SCHEMBL1810729

SCHEMBL1810729

O=[N+]([O-])c1nc(Br)ccc1OCCCBr

nearest known ligand 0.51

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ S1PR4 O95977 16/20 0.51
▸ NPC1 O15118 6/20 0.51
▸ RAB9A P51151 5/20 0.51
▸ SMN1; SMN2 Q16637 4/20 0.51
▸ MAPT P10636 4/20 0.51
▸ LMNA P02545 3/20 0.51
▸ HPGD P15428 3/20 0.51
▸ MEN1 O00255 2/20 0.51
▸ KMT2A Q03164 2/20 0.51
▸ ALDH1A1 P00352 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30454502 1.00 S1PR4 (0.51) S1PR4NPC1RAB9ASMN1; SMN2MAPT
SCHEMBL1812248 0.92 S1PR4 (0.52) S1PR4NPC1RAB9ASMN1; SMN2MAPT
SCHEMBL10292640 0.87 S1PR4 (0.56) S1PR4NPC1RAB9ASMN1; SMN2MAPT
SCHEMBL30365901 0.79 NPC1 (0.49) S1PR4NPC1RAB9ASMN1; SMN2MAPT
SCHEMBL2921634 0.78 ALDH1A1 (0.47) S1PR4NPC1RAB9ASMN1; SMN2MAPT
SCHEMBL2921638 0.78 ALDH1A1 (0.47) S1PR4NPC1RAB9ASMN1; SMN2MAPT
SCHEMBL18952542 0.78 S1PR4 (0.50) S1PR4NPC1RAB9ASMN1; SMN2MAPT
SCHEMBL23851490 0.77 S1PR4 (0.59) S1PR4NPC1RAB9AMAPTLMNA
SCHEMBL2673898 0.77 NPC1 (0.60) S1PR4NPC1RAB9ASMN1; SMN2MAPT
SCHEMBL18952588 0.77 S1PR4 (0.49) S1PR4NPC1RAB9ASMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260035362-A1 GLP-1R AGONISTS AND USES THEREOF QILU REGOR THERAPEUTICS INC (CN) 2026-02-05 — — US disclosed
US-12365670-B2 GLP-IR agonists and uses thereof QILU REGOR THERAPEUTICS INC. (CN) 2025-07-22 — — US disclosed
CN-113227068-B GLP-1R agonists and uses thereof 上海齐鲁锐格医药研发有限公司 2023-06-13 — — CN disclosed
US-20220024901-A1 GLP-1R AGONISTS AND USES THEREOF QILU REGOR THERAPEUTICS INC. (CN) 2022-01-27 — — US disclosed
CN-113227068-A GLP-1R agonists and uses thereof 上海齐鲁锐格医药研发有限公司 2021-08-06 — — CN disclosed
US-10844049-B2 GLP-1R agonists and uses thereof QILU REGOR THERAPEUTICS INC. (CN) 2020-11-24 — — US disclosed
US-20200283424-A1 GLP-1R AGONISTS AND USES THEREOF QILU REGOR THERAPEUTICS INC. (CN) 2020-09-10 — — US disclosed
US-20170305933-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-10-26 — — US disclosed
US-20170305933-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-10-26 — — US disclosed
US-9556201-B2 Bicyclic pyridines and analogs as sirtuin modulators GLAXOSMITHKLINE LLC (US) 2017-01-31 — — US disclosed
US-20160251376-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-09-01 — — US disclosed
US-20160251376-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-09-01 — — US disclosed
WO-2016138352-A1 TYK2 INHIBITORS AND USES THEREOF NIMBUS LAKSHMI, INC. (US) 2016-09-01 — — WO disclosed
EP-2493888-B1 BICYCLIC PYRIDINES AND ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC (US) 2016-04-06 — — EP disclosed
EP-2493888-B1 BICYCLIC PYRIDINES AND ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC (US) 2016-04-06 — — EP disclosed
CN-102725291-A Bicyclic pyridines and analogs as sirtuin modulators SIRTRIS PHARMACEUTICALS INC 2012-10-10 — — CN disclosed
US-20120252780-A1 BICYCLIC PYRIDINES AND ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC 2012-10-04 — — US disclosed
US-20120252780-A1 BICYCLIC PYRIDINES AND ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC 2012-10-04 — — US disclosed
EP-2493888-A1 BICYCLIC PYRIDINES AND ANALOGS AS SIRTUIN MODULATORS Sirtris Pharmaceuticals, Inc. (US) 2012-09-05 — — EP disclosed
WO-2011059839-A1 BICYCLIC PYRIDINES AND ANALOGS AS SIRTUIN MODULATORS SIRTRIS PHARMACEUTICALS, INC. (US) 2011-05-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260035362-A1 GLP-1R AGONISTS AND USES THEREOF GLP1R, GPR119, IAPP S1PR4 898/4885NPC1 342/4885RAB9A 1219/4885
US-10844049-B2 GLP-1R agonists and uses thereof GLP1R, GPR119, GIPR S1PR4 467/4885NPC1 706/4885RAB9A 1246/4885
US-12365670-B2 GLP-IR agonists and uses thereof GLP1R, GPR119, GIPR S1PR4 615/4885NPC1 786/4885RAB9A 1230/4885
US-20120252780-A1 BICYCLIC PYRIDINES AND ANALOGS AS SIRTUIN MODULATORS SIRT1, SIRT3, SIRT2 S1PR4 2465/4885NPC1 3795/4885RAB9A 1343/4885
US-20200283424-A1 GLP-1R AGONISTS AND USES THEREOF GLP1R, GPR119, GIPR S1PR4 467/4885NPC1 706/4885RAB9A 1246/4885
US-20220024901-A1 GLP-1R AGONISTS AND USES THEREOF GLP1R, GPR119, GIPR S1PR4 547/4885NPC1 609/4885RAB9A 1237/4885
US-20160251376-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 S1PR4 2816/4885NPC1 4595/4885RAB9A 3462/4885
US-20170305933-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 S1PR4 2816/4885NPC1 4595/4885RAB9A 3462/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.